First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer GroupMarinde J. G. Bond, Johanneke H.M.J.V. Vestjens, Helga Droogendijk et al.|The Lancet Oncology|2023Cited by 168
FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or <i>RAS</i>/<i>BRAFV600E-</i>mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.Cornelis J.A. Punt, Rutger‐Jan Swijnenburg, Marinde J. G. Bond et al.|Journal of Clinical Oncology|2022Cited by 14